A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
The Janus kinase (JAK) family of tyrosine kinases is associated with various cytokine receptors. JAK1 and JAK3 play particularly important roles in the immune response, and their inhibition is expected to provide targeted immune modulation. Several oral JAK inhibitors have recently been developed fo...
Saved in:
Main Authors: | Misato Ito (Author), Shunji Yamazaki (Author), Kaoru Yamagami (Author), Masako Kuno (Author), Yoshiaki Morita (Author), Kenji Okuma (Author), Koji Nakamura (Author), Noboru Chida (Author), Masamichi Inami (Author), Takayuki Inoue (Author), Shohei Shirakami (Author), Yasuyuki Higashi (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acneiform eruption during peficitinib treatment
by: Reiko Hara, et al.
Published: (2022) -
Peficitinib inhibits fibroblast-like synoviocyte activation and angiogenic vascular endothelial tube formation via inhibitory effects on PDGF and VEGF signaling in addition to JAK
by: Go Ishikawa, et al.
Published: (2022) -
Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis
by: Junko Toyoshima, et al.
Published: (2021) -
Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice
by: Shingo Sugahara, et al.
Published: (2022) -
Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects
by: Gao X, et al.
Published: (2022)